Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
07:00am, Wednesday, 07'th Jan 2026
NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd.
Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial
10:25am, Friday, 26'th Dec 2025
Biohaven Ltd (NYSE:BHVN) stock is down 3.2% to trade at $10.46 at last glance, amid reports that the biopharmaceutical name's drug to treat major depressive disorder did not meet the primary goal o
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise
09:24am, Friday, 26'th Dec 2025
BHVN's investment case definitely weakened after Opakalim's Phase 2 MDD miss. This also means they'll discontinue their psychiatric development. BHVN's pipeline remains diverse, but key assets like Op
Stock Futures Muted as Traders Return from Christmas Break
09:21am, Friday, 26'th Dec 2025
Stock futures are quiet as investors return from Christmas, with all three major indexes eyeing weekly gains
Biohaven Misses The Mark In Depression Trial, Stock Falls
08:20am, Friday, 26'th Dec 2025
On Wednesday, Biohaven Ltd. (NYSE: BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD).
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus
05:09am, Friday, 26'th Dec 2025
U.S. stock futures slipped on Friday after Wednesday's higher close. Futures of major benchmark indices fell.
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday
03:19am, Friday, 26'th Dec 2025
US stock futures slightly lower. Stocks to watch: NVIDIA, Dynavax, Sobr Safe, Davis Commodities, Biohaven.
ARS Investment Partners LLC Sells 85,577 Shares of Biohaven Ltd. $BHVN
03:19am, Thursday, 25'th Dec 2025
ARS Investment Partners LLC decreased its stake in shares of Biohaven Ltd. (NYSE: BHVN) by 7.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund
What Caused Biohaven (BHVN) Shares To Drop More Than 16% After Hours?
01:52am, Thursday, 25'th Dec 2025
Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial missed the primary endpoint.
Biohaven's depression drug fails mid-stage trial, shares fall
03:24pm, Wednesday, 24'th Dec 2025
Biohaven said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory setbacks for the drugmaker this year.
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
01:00pm, Wednesday, 24'th Dec 2025
NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd.
Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know
10:57am, Wednesday, 24'th Dec 2025
The consensus price target hints at an 88.6% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 19'th Dec 2025
Biohaven Ltd. (BHVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective respon
